Sainz Maria 4

What Happened

• Maria Sainz, a director of Pulse Biosciences (PLSE), was granted derivative equity awards on two dates: 50,000 shares on 2026-01-08 and 3,104 shares on 2026-02-05. Both grants are reported as derivative securities at $0.00 per share. These are awards (not open-market purchases or sales) and represent potential future ownership subject to vesting, not immediate cash proceeds.

Key Details

• Transaction dates and prices:
  • 2026-01-08: Grant of 50,000 derivative shares @ $0.00 (reported)
  • 2026-02-05: Grant of 3,104 derivative shares @ $0.00 (reported)
• Total shares granted: 53,104
• Shares owned after transaction: Not specified in this filing
• Filing date: 2026-02-06. The Jan 8 grant appears to have been reported late (Form 4s are generally required within 2 business days); the Feb 5 grant was reported the next day.
• Footnotes / vesting:
  • F1: For the 50,000 grant — one-third vests on the one-year anniversary of the grant, remaining shares vest monthly over the following two years, subject to continued service.
  • F2: For the 3,104 grant — vests in equal installments on March 5, 2026 and June 5, 2026, subject to continued service.

Context

• These were awards of derivative securities (described in the filing as "shares subject to the option") and not exercises or sales. The grants vest over time, so they convert to actual shares only as vesting conditions are met. Grants are common for directors and compensate service; they do not by themselves indicate the insider bought or sold shares or their market outlook.